Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

493
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
493
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
152
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

110
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deubiquitinase Josephin Domain-containing Protein 2 Promotes Acute Pancreatitis by Removing K63-linked Poly-ubiqutin Chain on Proliferating Cell Nuclear Antigen in Pancreatic Acinar Cells.

Cellular and molecular gastroenterology and hepatology·2025
Same author

Angiotensin II-induced phosphorylation of CHK1 at serine-280 drives cardiac remodelling by direct phosphorylation of JAK1, thus activating JAK1-STAT signalling in murine cardiomyocytes.

British journal of pharmacology·2025
Same author

Carnosol attenuates Ang II-induced renal injury by p62-KEAP1-NRF2 signaling pathway.

Toxicology and applied pharmacology·2025
Same author

β-elemene ameliorates metabolic dysfunction-associated steatohepatitis by targeting PPARα in experimental diet-induced models.

British journal of pharmacology·2025
Same author

Base-Promoted Tandem Synthesis of Indolo[1,2-<i>b</i>]isoquinolines from 2-Alkynylaniline and Nitroarenes.

The Journal of organic chemistry·2025
Same author

USP13 promotes hepatic stellate cells activation and aggravates liver fibrosis through deubiquitinating SMAD3.

Hepatology international·2025

Related Experiment Video

Updated: Jul 17, 2025

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

8.9K

Dual-Targeted Nanoparticle-in-Microparticle System for Ulcerative Colitis Therapy.

Yawen Zhang1, Yue Wu1, Yuping Yan1

  • 1School of Pharmacy, Hangzhou Medical College, 182 Tianmushan Rd, Hangzhou, 310013, China.

Advanced Healthcare Materials
|September 3, 2023
PubMed
Summary

This study developed a novel dual-targeted nanoparticle-in-microparticle system for ulcerative colitis (UC) treatment. The system effectively delivers Asiatic Acid to inflamed colon tissues, improving therapeutic outcomes by targeting macrophages and Caco-2 cells.

Keywords:
asiatic acidinflammation targetingnano-in-micro structureoral drug deliveryulcerative colitis

More Related Videos

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.2K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.3K

Related Experiment Videos

Last Updated: Jul 17, 2025

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
09:57

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

8.9K
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
09:01

Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy

Published on: May 22, 2020

3.2K
Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
07:05

Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation

Published on: December 15, 2017

8.3K

Area of Science:

  • Pharmacology
  • Biomedical Engineering
  • Gastroenterology

Background:

  • Conventional oral ulcerative colitis (UC) therapies face challenges with premature drug release and degradation in the gastrointestinal tract, limiting efficacy.
  • There is a need for advanced drug delivery systems to enhance therapeutic effectiveness and target inflamed colon tissues specifically.

Purpose of the Study:

  • To develop and evaluate a dual-targeted nanoparticle-in-microparticle (nano-in-micro) delivery system for Asiatic Acid (AA) to treat UC.
  • To investigate the pH-sensitive properties, cellular uptake mechanisms, and biodistribution of the developed AA-loaded delivery system (AA/CDM-BT-ALG).

Main Methods:

  • Preparation of a pH-sensitive nano-in-micro dual-targeted delivery system (AA/CDM-BT-ALG) loaded with Asiatic Acid.
  • Evaluation of cellular uptake via mannose receptor and biotin-mediated endocytosis in macrophages and Caco-2 cells.
  • Biodistribution studies in mice to assess colon accumulation and in vivo efficacy testing in colitis models.

Main Results:

  • The AA/CDM-BT-ALG system demonstrated targeted cellular absorption and enhanced intracellular drug concentration.
  • Biodistribution studies showed selective accumulation of microspheres in inflamed colon tissues with prolonged retention.
  • In vivo experiments revealed significant alleviation of colon histopathology, reduced inflammatory cell infiltration, and decreased pro-inflammatory cytokine expression in colitis mice.

Conclusions:

  • The developed dual-targeted nano-in-micro delivery system effectively targets inflamed colon tissues and enhances drug concentration.
  • AA/CDM-BT-ALG shows significant therapeutic potential for ulcerative colitis by modulating the TLR4/MyD88/NF-κB signaling pathway.
  • This system represents a promising approach for controlled drug release and improved treatment of UC.